Anemia in renal insufficiency.
In renal failure, severe anemia and associated fatigue, cognitive and sexual dysfunction have a significant impact on the patient's quality of life. Anemia has also been identified as an important etiologic factor in the development of left ventricular hypertrophy. The major cause of anemia in presence of a reduction of glomerular filtration rate is an inadequate production of a glycoprotein hormone, the erythropoietin (EPO). EPO is the primary regulator of the growth and survival of erythroid progenitor. The introduction of recombinant human erythropoietin (rHuEPO) has revolutionized the treatment of anemia in chronic renal failure. The vast majority of patients respond very well to treatment, but 5-10% of patients show some resistance to EPO, the most common cause of which is iron deficiency. Several studies are recently commenced to investigate the effects of preventing renal anemia ever developing. The target of hemoglobin concentration in pre-dialysis and dialysis patients are object of continuous re-examinations.
Division of Nephrology and Dialysis Policlinico S. Orsola-Malpighi, Bologna, Italy.
Antonio
A
Santoro
D000740:Anemia / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000503:physiopathology; D018450:Disease Progression; D004285:Dogs; D004351:Drug Resistance; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use; D006439:Hemodynamics; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D011788:Quality of Life; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D006435:Renal Dialysis; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin